Bover J, Górriz J L, Martín de Francisco A L, Caravaca F, Barril G, Molinero L M
Fundació Puigvert, Barcelona.
Nefrologia. 2008;28(6):637-43.
Since its publication in 2003, the K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease (CKD) have become a worldwide reference. The aim of this study was to analyze the observance to these guidelines in patients with a glomerular filtration rate < 60 ml/min/1,73m2 not yet included in dialysis in a Spanish multicenter cohort. A questionnaire by investigator/centre was completed by 32 different nephrologists participating in the OSERCE study and representing the overall Spanish public health net. We observed that biochemical parameters were measured less frequently than recommended, except in CKD stage 3. The therapeutic goals for intact PTH were not properly reported by 59 % of the consulted nephrologists for stages 3 and 4, whereas only 22% did not report them properly for stage 5. The goals for phosphorus were not adequately reported in 50 % of cases (stages 3 y 4) and 60 % (stage 5). For calcium, these values were 70 %, 73.3 % and 65.5 % for stages 3, 4 and 5, respectively. A corrected plasma calcium between 9.5 and 10.2 mg/dl is still considered adequate for 31%. As much as 87% nephrologists stated that they did not sistematically measure calcidiol plasma levels. In general, these results demonstrate that there is a great degree of unawareness of K/DOQITM predialysis guidelines. Thus, their poor implementation is probably not only due to the lower availability of approved therapeutic agents, the difficult achievement of goals or the disbelief on current recommendations. It would be desirable that forthcoming guidelines such as the KDIGO could also consider the need of educational efforts for CKD-Mineral and Bone Disorder.
自2003年发布以来,《慢性肾脏病(CKD)骨代谢与疾病的K/DOQI临床实践指南》已成为全球参考标准。本研究的目的是分析西班牙多中心队列中肾小球滤过率<60 ml/min/1.73m²且尚未开始透析的患者对这些指南的遵循情况。参与OSERCE研究并代表西班牙整个公共卫生网络的32位不同的肾病专家完成了由研究者/中心设计的问卷。我们观察到,除了CKD 3期外,生化参数的测量频率低于推荐频率。59%的参与咨询的肾病专家未正确报告3期和4期患者完整甲状旁腺激素(iPTH)的治疗目标,而5期患者中只有22%未正确报告。50%的病例(3期和4期)和60%(5期)未充分报告磷的治疗目标。对于钙,3期、4期和5期的这一比例分别为70%、73.3%和65.5%。31%的人仍认为校正后血浆钙在9.5至10.2 mg/dl之间是足够的。多达87%的肾病专家表示他们没有系统地测量血浆骨化二醇水平。总体而言,这些结果表明对K/DOQI™透析前指南的知晓程度很低。因此,其实施不佳可能不仅是由于获批治疗药物的可及性较低、难以实现目标或对当前建议存在怀疑。希望即将出台的指南,如KDIGO指南,也能考虑到对慢性肾脏病-矿物质和骨异常进行教育的必要性。